Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

262346.pdf (4.17 MB)

Document type

Article

Version

Accepted version

Publication date

2022-10-20

Publication license

cc-by-nc-nd (c) Elsevier B.V., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/210403

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.euroneuro.2022.10.004

Abstract

Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December, 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65-4.51) or mortality (RR=0.94; CI 0.81-1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02-0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76-4.85) and mortality (OR=1.53; CI 1.15-2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.

Subject

Psicofàrmacs, Metaanàlisi, Ressenyes sistemàtiques (Investigació mèdica), COVID-19, Antidepressius, Antipsicòtics

Subject (English)

Psychotropic drugs, Meta-analysis, Systematic reviews (Medical research), COVID-19, Antidepressants, Antipsychotic drugs

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

GÓMEZ-RAMIRO, Marta, et al. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. European Neuropsychopharmacology. 2022. Vol. 66, num. 30-44. ISSN 0924-977X. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/210403

Export metadata

JSON - METS

Share record